发布求助
文献互助 智能选刊 最新文献

Advanced Therapeutics最新文献

筛选
英文 中文
Issue Information (Adv. Therap. 3/2026) 发布信息（ad . Therap. 3/2026）
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2026-02-25 DOI: 10.1002/adtp.70136
{"title":"Issue Information (Adv. Therap. 3/2026)","authors":"","doi":"10.1002/adtp.70136","DOIUrl":"https://doi.org/10.1002/adtp.70136","url":null,"abstract":"","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 3","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.70136","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147568565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aptamer-Guided CRISPR Systems Delivery: Precision Targeting Strategies, Translational Barriers, and Therapeutic Potential 适体引导的CRISPR系统递送：精确靶向策略，翻译障碍和治疗潜力
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2026-02-25 DOI: 10.1002/adtp.202500395
Yousef Ijjeh, Nowar Alsarayreh, Dana Alqudah, Nirmeen Elzogheir, Ali Abuhaliema, Mohammad R. Shomali, Alqassem Abuarqoub, Mohammad IA Ahmad, Sharif Abdelghany, Alaaldin M. Alkilany, Walhan Alshaer
{"title":"Aptamer-Guided CRISPR Systems Delivery: Precision Targeting Strategies, Translational Barriers, and Therapeutic Potential","authors":"Yousef Ijjeh,&nbsp;Nowar Alsarayreh,&nbsp;Dana Alqudah,&nbsp;Nirmeen Elzogheir,&nbsp;Ali Abuhaliema,&nbsp;Mohammad R. Shomali,&nbsp;Alqassem Abuarqoub,&nbsp;Mohammad IA Ahmad,&nbsp;Sharif Abdelghany,&nbsp;Alaaldin M. Alkilany,&nbsp;Walhan Alshaer","doi":"10.1002/adtp.202500395","DOIUrl":"https://doi.org/10.1002/adtp.202500395","url":null,"abstract":"<div>\u0000 \u0000 <p>The CRISPR system has revolutionized genome editing due to its capability to modify genetic material with precision, programmability, and potential for treating disorders, cancers, and autoimmune diseases. Its use in the clinic is constrained by delivery inefficiencies, off-target effects, and immunogenicity. Aptamers have been touted as a solution to overcoming these constraints, as they are short, single-stranded nucleic acids that possess high specificity and affinity for cellular targets. This review highlights the convergence of aptamer technology and CRISPR-Cas9 delivery, with the focus on conjugation chemistries to engineer targeted delivery systems. This review discusses various aptamer-functionalized platforms, including lipid nanoparticles, polymeric carriers, gold nanoparticles, and DNA/RNA nanostructures, and their potential for cellular uptake, endosomal release, and site-specific genome editing. Therapeutic uses in cancer gene editing, immune cell engineering, and gene correction of genetic diseases are discussed, along with the translational hurdles, including aptamer and CRISPR components stability, immunogenicity, off-targeting, and manufacturing. Finally, future directions include the combination of aptamer-directed systems with next-generation genome sequencing, artificial intelligence-aided aptamer design, and addressing the regulatory challenges associated with clinical use. By leveraging the molecular selectivity of aptamers, this strategy could lead to a family of safe, efficacious, and targeted gene therapeutics.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 3","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147568835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aptamer-Guided CRISPR Systems Delivery: Precision Targeting Strategies, Translational Barriers, and Therapeutic Potential 适体引导的CRISPR系统递送：精确靶向策略，翻译障碍和治疗潜力
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2026-02-25 DOI: 10.1002/adtp.202500395
Yousef Ijjeh, Nowar Alsarayreh, Dana Alqudah, Nirmeen Elzogheir, Ali Abuhaliema, Mohammad R. Shomali, Alqassem Abuarqoub, Mohammad IA Ahmad, Sharif Abdelghany, Alaaldin M. Alkilany, Walhan Alshaer
{"title":"Aptamer-Guided CRISPR Systems Delivery: Precision Targeting Strategies, Translational Barriers, and Therapeutic Potential","authors":"Yousef Ijjeh,&nbsp;Nowar Alsarayreh,&nbsp;Dana Alqudah,&nbsp;Nirmeen Elzogheir,&nbsp;Ali Abuhaliema,&nbsp;Mohammad R. Shomali,&nbsp;Alqassem Abuarqoub,&nbsp;Mohammad IA Ahmad,&nbsp;Sharif Abdelghany,&nbsp;Alaaldin M. Alkilany,&nbsp;Walhan Alshaer","doi":"10.1002/adtp.202500395","DOIUrl":"https://doi.org/10.1002/adtp.202500395","url":null,"abstract":"<div>\u0000 \u0000 <p>The CRISPR system has revolutionized genome editing due to its capability to modify genetic material with precision, programmability, and potential for treating disorders, cancers, and autoimmune diseases. Its use in the clinic is constrained by delivery inefficiencies, off-target effects, and immunogenicity. Aptamers have been touted as a solution to overcoming these constraints, as they are short, single-stranded nucleic acids that possess high specificity and affinity for cellular targets. This review highlights the convergence of aptamer technology and CRISPR-Cas9 delivery, with the focus on conjugation chemistries to engineer targeted delivery systems. This review discusses various aptamer-functionalized platforms, including lipid nanoparticles, polymeric carriers, gold nanoparticles, and DNA/RNA nanostructures, and their potential for cellular uptake, endosomal release, and site-specific genome editing. Therapeutic uses in cancer gene editing, immune cell engineering, and gene correction of genetic diseases are discussed, along with the translational hurdles, including aptamer and CRISPR components stability, immunogenicity, off-targeting, and manufacturing. Finally, future directions include the combination of aptamer-directed systems with next-generation genome sequencing, artificial intelligence-aided aptamer design, and addressing the regulatory challenges associated with clinical use. By leveraging the molecular selectivity of aptamers, this strategy could lead to a family of safe, efficacious, and targeted gene therapeutics.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 3","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147568836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Issue Information (Adv. Therap. 3/2026) 发布信息（ad . Therap. 3/2026）
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2026-02-25 DOI: 10.1002/adtp.70136
{"title":"Issue Information (Adv. Therap. 3/2026)","authors":"","doi":"10.1002/adtp.70136","DOIUrl":"10.1002/adtp.70136","url":null,"abstract":"","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 3","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://advanced.onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.70136","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147568837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2026-02-25
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 3","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148123056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2026-02-25
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 3","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148121327","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2026-02-25
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 3","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148123057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Aptamer-Guided CRISPR Systems Delivery: Precision Targeting Strategies, Translational Barriers, and Therapeutic Potential 适体引导的CRISPR系统递送：精确靶向策略，翻译障碍和治疗潜力
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2026-02-25 DOI: 10.1002/adtp.202500395
Yousef Ijjeh, Nowar Alsarayreh, Dana Alqudah, Nirmeen Elzogheir, Ali Abuhaliema, Mohammad R. Shomali, Alqassem Abuarqoub, Mohammad IA Ahmad, Sharif Abdelghany, Alaaldin M. Alkilany, Walhan Alshaer
{"title":"Aptamer-Guided CRISPR Systems Delivery: Precision Targeting Strategies, Translational Barriers, and Therapeutic Potential","authors":"Yousef Ijjeh,&nbsp;Nowar Alsarayreh,&nbsp;Dana Alqudah,&nbsp;Nirmeen Elzogheir,&nbsp;Ali Abuhaliema,&nbsp;Mohammad R. Shomali,&nbsp;Alqassem Abuarqoub,&nbsp;Mohammad IA Ahmad,&nbsp;Sharif Abdelghany,&nbsp;Alaaldin M. Alkilany,&nbsp;Walhan Alshaer","doi":"10.1002/adtp.202500395","DOIUrl":"10.1002/adtp.202500395","url":null,"abstract":"<div>\u0000 \u0000 <p>The CRISPR system has revolutionized genome editing due to its capability to modify genetic material with precision, programmability, and potential for treating disorders, cancers, and autoimmune diseases. Its use in the clinic is constrained by delivery inefficiencies, off-target effects, and immunogenicity. Aptamers have been touted as a solution to overcoming these constraints, as they are short, single-stranded nucleic acids that possess high specificity and affinity for cellular targets. This review highlights the convergence of aptamer technology and CRISPR-Cas9 delivery, with the focus on conjugation chemistries to engineer targeted delivery systems. This review discusses various aptamer-functionalized platforms, including lipid nanoparticles, polymeric carriers, gold nanoparticles, and DNA/RNA nanostructures, and their potential for cellular uptake, endosomal release, and site-specific genome editing. Therapeutic uses in cancer gene editing, immune cell engineering, and gene correction of genetic diseases are discussed, along with the translational hurdles, including aptamer and CRISPR components stability, immunogenicity, off-targeting, and manufacturing. Finally, future directions include the combination of aptamer-directed systems with next-generation genome sequencing, artificial intelligence-aided aptamer design, and addressing the regulatory challenges associated with clinical use. By leveraging the molecular selectivity of aptamers, this strategy could lead to a family of safe, efficacious, and targeted gene therapeutics.</p>\u0000 </div>","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 3","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147568567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Issue Information (Adv. Therap. 3/2026) 发布信息（ad . Therap. 3/2026）
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2026-02-25 DOI: 10.1002/adtp.70136
{"title":"Issue Information (Adv. Therap. 3/2026)","authors":"","doi":"10.1002/adtp.70136","DOIUrl":"https://doi.org/10.1002/adtp.70136","url":null,"abstract":"","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 3","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://advanced.onlinelibrary.wiley.com/doi/epdf/10.1002/adtp.70136","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147568566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 2.6 4区 医学
Advanced Therapeutics Pub Date : 2026-02-22
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":7284,"journal":{"name":"Advanced Therapeutics","volume":"9 2","pages":""},"PeriodicalIF":2.6,"publicationDate":"2026-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148118031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书